Company: TLSA
Filing Date: 2025-05-15
Form Type: 6-K
Source: 0001213900-25-043694
Chunk: 0

Company: Tiziana Life Sciences Ltd
Filing Date: 2025-05-15
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

May 2025

Commission File Number: 001-38723

Tiziana Life Sciences LTD

(Exact Name of Registrant as Specified in Its Charter)

9 thFloor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive
office)</div>

Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.

<div align='center'>Form 20-F☒Form 40-F☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K</div>

On May 15, 2025, Tiziana Life Sciences LTD (the “”)
issued this 6K announcing, the publication of a new study in the Journal of ‘Clinical Nuclear Medicine’ demonstrating that
intranasal administration of foralumab significantly dampened microglial activation in a 78-year old patient with moderate Alzheimer's
disease (AD) treated as part of a Food and Drug Administration (FDA) expanded access program. The findings, published in the prestigious
‘Clinical Nuclear Medicine’ journal, highlight a promising avenue in the treatment of neurological disorders. This case represents
the first use of 18F-PBR06-PET in a patient with moderate AD dementia and the first published report of an AD patient treated with nasal-foralumab.
The study, led by Dr. Tarun Singhal and Dr. Howard Weiner of Brigham and Women’s Hospital, a founding member of the Mass General
Brigham healthcare system, utilized advanced PET imaging with the [F-18]PBR06 tracer to assess microglial activation before and after
treatment. The findings revealed a notable reduction in neuroinflammation following intranasal foralumab administration., a copy of which
is furnished as Exhibit 99.1

The Announcement is furnished herewith as Exhibit
99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed”
for the purposes of Section 18 of the Securities Exchange Act